- Home
- STTK vs VIGL Comparison
STTK vs VIGL Comparison
Compare STTK & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- VIGL
- Stock Information
- Founded
- STTK 2016
- VIGL 2020
- Country
- STTK United States
- VIGL United States
- Employees
- STTK N/A
- VIGL N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- VIGL Health Care
- Exchange
- STTK Nasdaq
- VIGL Nasdaq
- Market Cap
- STTK 56.8M
- VIGL 95.2M
- IPO Year
- STTK 2020
- VIGL 2022
- Fundamental
- Price
- STTK $1.12
- VIGL $1.78
- Analyst Decision
- STTK Hold
- VIGL Strong Buy
- Analyst Count
- STTK 3
- VIGL 5
- Target Price
- STTK $2.00
- VIGL $19.75
- AVG Volume (30 Days)
- STTK 182.2K
- VIGL 305.8K
- Earning Date
- STTK 02-27-2025
- VIGL 11-07-2024
- Dividend Yield
- STTK N/A
- VIGL N/A
- EPS Growth
- STTK N/A
- VIGL N/A
- EPS
- STTK N/A
- VIGL N/A
- Revenue
- STTK $6,435,000.00
- VIGL N/A
- Revenue This Year
- STTK $313.04
- VIGL N/A
- Revenue Next Year
- STTK N/A
- VIGL N/A
- P/E Ratio
- STTK N/A
- VIGL N/A
- Revenue Growth
- STTK 382.75
- VIGL N/A
- 52 Week Low
- STTK $0.94
- VIGL $1.49
- 52 Week High
- STTK $11.76
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- VIGL 40.73
- Support Level
- STTK $1.13
- VIGL $1.49
- Resistance Level
- STTK $1.39
- VIGL $2.10
- Average True Range (ATR)
- STTK 0.11
- VIGL 0.17
- MACD
- STTK 0.00
- VIGL 0.06
- Stochastic Oscillator
- STTK 18.18
- VIGL 47.54
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.